top of page

Premier auteur: Echerbault et al.

Lien vers l'article: DOI: 10.1093/rheumatology/keae123


Comparing clinical features between males and females with VEXAS syndrome

Abstract

Objectives: VEXAS syndrome is an autoinflammatory disease associated with a somatic mutation of the X-linked UBA1 gene in haematopoietic progenitor cells. This disorder was originally described as a disease affecting men, but rare cases of VEXAS syndrome in women have since been reported. The theoretical existence of phenotypic sex differences in this X-linked disease is debated. We compared the features of VEXAS syndrome between males and females to better understand this disorder and to improve its diagnostic accuracy in females.


Methods: From previously published clinical descriptions of VEXAS syndrome, we included studies that described patients with precise, individual VEXAS-related features. We formed a literature-based cohort of patients by collecting their clinical and biological data and compared the characteristics of male and female patients.


Results: We gathered 224 patient descriptions from 104 articles: 9 women and 215 men. Among the women, 1 had a constitutional 45,X karyotype and 4 had an acquired X monosomy in the bone marrow karyotype, while the marrow karyotype was not provided for the others. No difference was observed in the clinical or biological features according to sex. We also observed no difference in the type of UBA1 mutation or the association with myelodysplastic syndrome.


Conclusions: Our results supported the hypothesis that the UBA1 mutation should be sought under the same conditions in both sexes. As UBA1 is not subject to X-chromosome inactivation, VEXAS syndrome in females requires both UBA1 mutation and X monosomy, thus explaining the similarity between male and female VEXAS-related features and the lower prevalence of VEXAS syndrome in females.



 
 
 

First author: Terré et al.

Link to article: DOI: 10.1111/bjh.19383


Waldenstrom macroglobulinaemia with AA amyloidosis

Summary

Waldenström macroglobulinemia (WM) is a rare malignant hematopathy characterized by lymphoplasmacytic lymphoma (LPL) secreting IgM. Some patients with WM exhibit chronic inflammation, sometimes complicated by AA amyloidosis, which involves the deposition of insoluble fibrils derived from serum amyloid A (SAA) protein. However, the underlying mechanism of this inflammation remains poorly understood.


We report the case of an 86-year-old female patient with WM complicated by AA amyloidosis. Whole-exome sequencing (WES) revealed a somatic mutation in NLRP2 restricted to B cells. We investigated the functional consequences of this mutation.


The analyses showed that the NLRP2 p.Asp121Gly mutation leads to a reduction in ASC aggregation, a marker of inflammasome activation. In a WM model, the loss of NLRP2 resulted in an increased secretion of CCL-5, a cytokine promoting IL-6 production by stromal cells. IL-6 is a key factor in the induction of SAA, and our results suggest that the NLRP2 mutation may have contributed to the development of AA amyloidosis in this patient.


These findings highlight the importance of somatic mutations in inflammatory regulation and the need for further studies to clarify the role of NLRP2 in the pathophysiology of inflammatory WM (IWM).





 
 
 

First author: Naqib Ullah

Journal: Cureus

Reference : DOI : 10.7759/cureus.49533


Article sur Néphrite tubulointerstitielle aiguë et amylose rénale

Introduction:

Lung cancer is the second most common malignancy. The two types of lung cancer are small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Among current treatments, anti-PD-1 or anti-PD-L1 agents (checkpoint inhibitors (PKIs): pembrolizumab and atezolizumab) represent adjuvant therapy in lung cancer. The most frequently reported adverse events with ICPs are diarrhea, pneumopathy and drug-induced hepatitis.


The authors report here the case of a 70-year-old man who received Atezolizumab as adjuvant therapy and developed nephrotic-like proteinuria, revealing AA amyloidosis and atezolizumab-induced interstitial nephritis.



 
 
 
bottom of page